健脾益肾方联合非奈利酮治疗2型糖尿病肾病早中期阶段临床研究

Clinical Study on Jianpi Yishen Prescription Combined with Fenalidone for Type 2 Diabetes Kidney Disease in Early and Middle Stages

目的:观察健脾益肾方联合非奈利酮治疗2型糖尿病肾病早中期阶段的临床效果。方法:选取60例2型糖尿病肾病早中期阶段的患者作为研究对象,采取随机数字表法分为对照组和观察组各30例。2组均给予常规治疗控制血糖、血压,并告知患者适当运动,合理膳食。对照组在常规治疗基础上给予非奈利酮片口服,观察组在对照组基础上给予健脾益肾方治疗。比较2组糖化血红蛋白(HbA1c)、尿素氮(BUN)、估算的肾小球滤过率(eGFR)、尿微量白蛋白/尿肌酐比值(UACR)以及血钾(K)水平。结果:治疗后,2组HbA1c、BUN、eGFR、K比较,差异无统计学意义(P>0.05)。治疗后,2组UACR水平低于治疗前(P<0.05),且观察组UACR水平低于对照组(P<0.05)。结论:健脾益肾方联合非奈利酮治疗糖尿病肾病早中期阶段可以通过减少尿蛋白,以减轻肾脏损伤,保护肾功能,延缓疾病的进一步发展。

Objective:To observe the clinical effect of Jianpi Yishen Prescription combined with Fenalidone on type 2 diabetes kidney disease in the early and middle stages.Methods:A total of 60 cases of patients with type 2 diabetes kidney disease in the early and middle stages were selected as the study subjects and divided into the control group and the observation group according to the random number table method,with 30 cases in each group.The two groups were given conventional treatment to control blood glucose and blood pressure,and all patients were informed to exercise appropriately and have a reasonable diet.The control group was given the oral administration of Fenalidone Tablets based on conventional treatment,and the observation group was additionally treated with Jianpi Yishen Prescription based on the treatment of the control group.The detection results of glycated hemoglobin(HbA1c),urea nitrogen(BUN),estimated glomerular filtration rate(eGFR),urinary microalbumin-to-creatinine ratio(UACR),and blood potassium(K)were compared between the two groups.Results:After treatment,there was no significant difference being found in HbA1c,BUN,eGFR,and K between the two groups(P>0.05).After treatment,the UACR levels in the two groups were lower than those before treatment(P<0.05),and the UACR levels in the observation group were lower than those in the control group(P<0.05).Conclusion:Jianpi Yishen Prescription combined with Fenalidone can reduce urinary protein to alleviate kidney damage in the treatment of type 2 diabetes kidney disease in the early and middle stages,protect kidney function,and delay further disease progression.